Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening

Our objective was to determine whether multivariate algorithms based on serum total PSA, the free proportion of PSA, age, digital rectal examination and prostate volume can reduce the rate of false‐positive PSA results in prostate cancer screening more effectively than the proportion of free PSA alone at 95% sensitivity. A total of 1,775 consecutive 55‐ to 67‐year‐old men with a serum PSA of 4–10 μg/l in the European Randomized Study of Screening for Prostate Cancer were included. To predict the presence of cancer, multivariate algorithms were constructed using logistic regression (LR) and a multilayer perceptron neural network with Bayesian regularization (BR‐MLP). A prospective setting was simulated by dividing the data set chronologically into one set for training and validation (67%, n = 1,183) and one test set (33%, n = 592). The diagnostic models were calibrated using the training set to obtain 95% sensitivity. When applied to the test set, the LR model, the BR‐MLP model and the proportion of free PSA reached 92%, 87% and 94% sensitivity and reduced 29%, 36% and 22% of the false‐positive PSA results, respectively. At a fixed sensitivity of 95% in the test set, the LR model eliminated more false‐positive PSA results (22%) than the proportion of free PSA alone (17%) (p < 0.001), whereas the BR‐MLP model did not (19%) (p = 0.178). The area under the ROC curve was larger for the LR model (0.764, p = 0.030) and the BR‐MLP model (0.760, p = 0.049) than for the proportion of free PSA (0.718). A multivariate algorithm can be used to reduce unnecessary prostate biopsies in screening more effectively than the proportion of free PSA alone, but the algorithms will require updating when clinical practice develops with time. © 2004 Wiley‐Liss, Inc.

[1]  U. Stenman,et al.  Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. , 1999, Clinical chemistry.

[2]  H. D. de Koning,et al.  Health‐related quality of life in patients with screen‐detected versus clinically diagnosed prostate cancer preceding primary treatment , 2001, The Prostate.

[3]  F. Schröder,et al.  Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. , 1997, Urology.

[4]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[5]  R. Renzetti The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update , 1999 .

[6]  T. Tammela,et al.  Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. , 2002, Urology.

[7]  V. Nelen,et al.  Prostate volume and cancer in screening programs , 1997, The Prostate.

[8]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[9]  F. Schröder,et al.  The European Randomized Study of Screening for Prostate Cancer (ERSPC): An Update , 1999, European Urology.

[10]  J. Hugosson,et al.  Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.

[11]  P. Walsh Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.

[12]  J. Hugosson,et al.  Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region) , 1999, The Prostate.

[13]  U. Stenman,et al.  Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. , 1993, Clinical chemistry.

[14]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .

[15]  B. G. Blijenberg,et al.  The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. , 1995, Urology.

[16]  P Finne,et al.  Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. , 2000, Urology.

[17]  A. Zlotta,et al.  Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. , 2001, The Journal of urology.

[18]  T. Tammela,et al.  Three-year results of the Finnish prostate cancer screening trial. , 2001, Journal of the National Cancer Institute.

[19]  Klaus Jung,et al.  Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. , 2002, Clinical chemistry.

[20]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[21]  Martin T. Hagan,et al.  Gauss-Newton approximation to Bayesian learning , 1997, Proceedings of International Conference on Neural Networks (ICNN'97).

[22]  Dietmar Schnorr,et al.  An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation , 2002, International journal of cancer.

[23]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[24]  B. G. Blijenberg,et al.  The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. , 1997, The Journal of urology.

[25]  Mesut Remzi,et al.  Novel artificial neural network for early detection of prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[27]  G Bartsch,et al.  The problem of cutoff levels in a screened population , 2001, Cancer.

[28]  David J. C. MacKay,et al.  Bayesian Interpolation , 1992, Neural Computation.

[29]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.